BetaNo officer or director has bought or sold Kailera Therapeutics, Inc. stock in the past 12 months. An outside holder did trade in that period: RTW INVESTMENTS, LP bought shares and Bain Capital Life Sciences Investors, LLC bought shares. Outside holders are reported separately.
Nothing notable: no open-market sales or purchases by officers or directors in this period.
No officer or director sold shares in this period. 15 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: John Milligan, Scott Akamine, Frank Clyburn, Ronald Renaud Jr., Paula Cloghessy, Christopher Hite, Martin Mackay, Jamie Coleman, Douglas Pagan, Scott Wasserman, Paul Burgess, Andrew Kaplan, Adam Koppel, Kathleen Tregoning and Nur Nicholson (share of stake is being verified).
No officer or director trades were reported for the past 30 days.
Jiangsu Hengrui Pharmaceuticals Co., Ltd., Stuart Partners, LLC and CANADA PENSION PLAN INVESTMENT BOARD and 5 more reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.
No. Ronald Renaud Jr. reported no open-market sales in the past 12 months.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|
Board members representing outside shareholders, reported separately: Andrew Kaplan, Adam Koppel. Details
Outside holder, reported separately: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: Stuart Partners, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: CANADA PENSION PLAN INVESTMENT BOARD (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: RTW INVESTMENTS, LP (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: Bain Capital Life Sciences Investors, LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: BAIN CAPITAL INVESTORS LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
John Milligan!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for John Milligan are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for John MilliganHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Milligan are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Scott Akamine!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Scott Akamine are complete. Chief Legal Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Scott AkamineHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Scott Akamine are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Frank Clyburn!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Frank Clyburn are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Frank ClyburnHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Frank Clyburn are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Ronald Renaud Jr.!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ronald Renaud Jr. are complete. CEO & President, Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Ronald Renaud Jr.Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ronald Renaud Jr. are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Paula Cloghessy!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Paula Cloghessy are complete. Chief People Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Paula CloghessyHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Paula Cloghessy are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Christopher Hite!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Christopher Hite are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Christopher HiteHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Hite are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Martin Mackay!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Martin Mackay are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Martin MackayHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Martin Mackay are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Jamie Coleman!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jamie Coleman are complete. Chief Commercial Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Jamie ColemanHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jamie Coleman are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Douglas Pagan!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Douglas Pagan are complete. Chief Financial Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Douglas PaganHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Douglas Pagan are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Scott Wasserman!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Scott Wasserman are complete. Chief Medical Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Scott WassermanHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Scott Wasserman are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Paul Burgess!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Paul Burgess are complete. Chief Operating Officer & Chief Business Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Paul BurgessHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Paul Burgess are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Andrew Kaplan!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Andrew Kaplan are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Andrew KaplanHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Kaplan are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Adam Koppel!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Adam Koppel are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Adam KoppelHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adam Koppel are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Kathleen Tregoning!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kathleen Tregoning are complete. Chief Corporate Affairs Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Kathleen TregoningHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kathleen Tregoning are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Nur Nicholson!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Nur Nicholson are complete. Chief Technology Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Nur NicholsonHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nur Nicholson are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Apr 20, 2026), not a market close. | ||||||||||||||||||||||||||||||||||||||||||||
Holdings and share of stake for Kailera Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.
| Board member | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held |
|---|---|---|---|---|
Andrew Kaplan!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Andrew Kaplan are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Andrew KaplanHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Andrew Kaplan are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Adam Koppel!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Adam Koppel are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Adam KoppelHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Adam Koppel are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Kailera Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 42 Forms 3, 4 and 5 on record for Kailera Therapeutics, Inc. (SEC CIK 2096997), filed from Apr 16, 2026 to Sep 9, 2026; 42 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
| Name | Last filed | Last reported balance |
|---|---|---|
| Yuting Liu | No balance on record |
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.